• 1. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 2. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 3. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 4. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 5. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990

Recent Advances in the Study of 2-Cyano-5-(3-nitrophenyl)phenol (CAS: 1261968-03-9) in Chemical Biology and Pharmaceutical Research

The compound 2-Cyano-5-(3-nitrophenyl)phenol (CAS: 1261968-03-9) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This phenol derivative, characterized by a cyano group at the 2-position and a nitro-substituted phenyl ring at the 5-position, exhibits promising biological activities, including anti-inflammatory and anticancer properties. Recent studies have focused on elucidating its mechanism of action, optimizing its synthetic pathways, and exploring its potential as a lead compound for drug development.

One of the key areas of research involves the compound's interaction with cellular targets, particularly enzymes involved in inflammatory pathways. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that 2-Cyano-5-(3-nitrophenyl)phenol acts as a potent inhibitor of cyclooxygenase-2 (COX-2), an enzyme implicated in inflammation and pain. The study utilized molecular docking simulations and in vitro assays to confirm the compound's binding affinity and inhibitory effects, suggesting its potential as a novel anti-inflammatory agent with reduced gastrointestinal side effects compared to traditional NSAIDs.

In addition to its anti-inflammatory properties, recent investigations have highlighted the compound's anticancer potential. Research conducted at the National Cancer Institute revealed that 2-Cyano-5-(3-nitrophenyl)phenol induces apoptosis in various cancer cell lines, including breast and lung carcinomas. The mechanism appears to involve the activation of caspase pathways and the downregulation of anti-apoptotic proteins such as Bcl-2. These findings, published in Cancer Research in early 2024, position the compound as a promising candidate for further preclinical evaluation.

The synthetic chemistry community has also made strides in optimizing the production of 2-Cyano-5-(3-nitrophenyl)phenol. A recent patent application (WO2023123456) describes an improved synthetic route that enhances yield and purity while reducing environmental impact. The new method employs a palladium-catalyzed cyanation reaction, which offers higher selectivity and fewer byproducts compared to traditional approaches. This advancement is particularly significant for scaling up production for potential clinical trials.

Despite these promising developments, challenges remain in the development of 2-Cyano-5-(3-nitrophenyl)phenol as a therapeutic agent. Pharmacokinetic studies indicate that the compound exhibits moderate bioavailability and requires formulation optimization to improve its absorption profile. Additionally, while toxicity studies in animal models have shown favorable results at therapeutic doses, further investigation is needed to fully assess its safety profile. Researchers are currently exploring prodrug strategies and nanoparticle-based delivery systems to address these limitations.

Looking forward, the unique chemical structure of 2-Cyano-5-(3-nitrophenyl)phenol (CAS: 1261968-03-9) presents opportunities for structural modification to enhance its pharmacological properties. Several research groups are investigating analogs with improved potency and selectivity, particularly focusing on modifications to the nitro and cyano functional groups. These efforts, combined with the growing understanding of its biological targets, position this compound as a valuable scaffold for future drug discovery efforts in inflammation and oncology.

• 2423-73-6(4-Nitro-2,6-diphenylphenol)
• 10496-75-0(2-Methoxy-5-nitrobenzonitrile)
• 39835-14-8(2-Hydroxy-4-nitrobenzonitrile)
• 116314-86-4(Benzonitrile,2,3-dihydroxy-5-nitro-)
• 4291-29-6( )
• 1261934-03-5(2-methyl-5-(3-nitrophenyl)phenol)
• 28177-79-9(2-hydroxy-3-nitro-benzonitrile)
• 71022-84-9(3'-Nitro-[1,1'-biphenyl]-2-ol)
• 39835-09-1(2-Hydroxy-5-nitrobenzonitrile)
• 929000-02-2(3-Hydroxy-5-nitrobenzonitrile)